Faculty Opinions recommendation of Primary tumor location as a prognostic factor in metastatic colorectal cancer.

2018 ◽  
Author(s):  
Sebastian Stintzing
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location

scholarly journals RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

2015 ◽  
Vol 107 (9) ◽  
pp. djv203 ◽  
Author(s):  
Felice N. van Erning ◽  
Marloes A. Elferink ◽  
Amanda C. R. K. Bos ◽  
Valery E. P. P. Lemmens
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location

scholarly journals Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

2015 ◽  
Vol 107 (3) ◽  
Author(s):  
Fotios Loupakis ◽  
Dongyun Yang ◽  
Linda Yau ◽  
Shibao Feng ◽  
Chiara Cremolini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location

scholarly journals Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries

2021 ◽  
Author(s):  
George Kafatos ◽  
Victoria Banks ◽  
Peter Burdon ◽  
David Neasham ◽  
Kimberly A Lowe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Treatment Strategies ◽  
Treatment Decisions ◽  
Tumor Location ◽  
First Line ◽  
Primary Tumor Location ◽  
The Uk ◽  
Prognostic And Predictive Factors

Background: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often administered to patients with RAS wild-type mCRC and those with left-sided tumors, while anti-VEGF mAbs were preferred in RAS mutant and right-sided tumors. Adopted treatment strategies differed between countries, largely due to reimbursement. Conclusion: Biomarker status and primary tumor location steered treatment decisions in first line. Adopted treatment strategies differed between participating countries.

scholarly journals Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population.

2017 ◽  
Vol 28 ◽  
pp. iii118-iii119
Author(s):  
Gonçalo Atalaia ◽  
Marta Vaz Baptista ◽  
Tiago Tomás ◽  
Susana Almeida ◽  
Inês Eiriz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Analysis ◽  
Primary Tumor ◽  
Tumor Location ◽  
Prognostic Impact ◽  
Primary Tumor Location

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study

2020 ◽  
Vol 19 (3) ◽  
pp. 200-208.e1 ◽  
Author(s):  
Benoist Chibaudel ◽  
Thierry André ◽  
Christophe Tournigand ◽  
Christophe Louvet ◽  
Magdalena Benetkiewicz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Tumor Location ◽  
Phase Iii ◽  
Primary Tumor Location ◽  
Post Hoc Analysis ◽  
Phase Iii Study ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document